Research Article
Pretreatment with AM1241 Enhances the Analgesic Effect of Intrathecally Administrated Mesenchymal Stem Cells
Figure 6
Administration of TGF-β1-neutralizing Ab on neuropathic pain and expression of p-ERK1/2. (a) Timeline of the time of BMSC, AM1241, and BMSCs pretreated with AM1241 injections (CCI day 5), the time of TGF-β-neutralizing Ab (day 5 after treatment), and tissue collection (day 5 after treatment and 3 h after TGF-β-neutralizing Ab injection). (b, c) The reversal of BMSC- and BMSCs pretreated with AM1241-induced (b) mechanical and (c) thermal analgesia at 3 h after i.t. injection of TGF-β-neutralizing Ab. (d, e) WB analysis of p-ERK1/2 expression in all treatment groups after i.t. injection of TGF-β-neutralizing Ab; mice/group. (f, g) Expression of p-ERK1/2 via immunofluorescence in the BMSC and BMSCs pretreated with AM1241 groups in the spinal dorsal horn after i.t. injection of TGF-β-neutralizing Ab; mice/group. (g) Quantification results of p-ERK1/2 staining. Scale bar, 100 μm. , , and versus the sham group; , , and versus the CCI group; , , and versus the AM1241+TGF-β Ab group. Arrows in (b) and (c) indicate the time of BMSC, AM1241, and BMSCs pretreated with AM1241 injections and the time of TGF-β-neutralizing Ab injection, respectively.
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |